Ischemia Clinical Trial
— NIRVANAOfficial title:
Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment
Verified date | January 2018 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of project is to answer fundamental questions about the mechanisms underlying
mental stress ischemia in patients with coronary artery disease, mood disorders, or both, and
to identify potential biomarkers and psychosocial risk factors associated with this
condition.
To achieve this goal, investigators will use cutting-edge cardiovascular and functional
neuroimaging tools to study mental stress ischemia in a carefully controlled laboratory
setting in subjects recruited from four patient populations: 1) patients who recently
sustained a myocardial infarction; 2) patients undergoing non-emergent invasive coronary
angiography (with and without known coronary artery disease); 3) patients with a diagnosis of
major depressive disorder; and 4) patients with a diagnosis of bipolar 1 or bipolar 2
disorder.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria for Cardiac Subjects: 1. Male and female subjects, ages 50 years or more 2. Able to provide informed consent. Must be fluent english speakers. 3. Known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test or invasive coronary angiography (ICA) 4. Patients that are hemodynamically stable Exclusion Criteria for Cardiac subjects: 1. Evidence of ongoing myocardial infarction or homonymic instability 2. Positive pregnancy test or unknown pregnant state at the time of enrollment for all women of child-bearing potential 3. Known contraindications to cardiovascular CT angiography with intravenous contrast (A) Known allergies (B) Renal dysfunction (GFR < 30ml/min) (C) Contraindications to beta-blockers or nitroglycerin or adenosine (D) Irregular heart rate not controlled by administration of beta-blockers 4. Patients with contraindications to MRI scans (A) Non-MR compatible device or material implant (B) Known allergies to gadolinium containing contrast agent (C) Renal dysfunction (GFR < 30 ml/min) Inclusion Criteria for Psychiatric Subjects 1. Male and female subjects, ages 50 years or more 2. Must be fluent English-speakers due to the design of the mental stress tasks. Able to provide informed consent. 3. Subjects who are stable and meet DSM-V criteria for a diagnosis of major depressive disorder, bipolar 1 disorder, or bipolar 2 disorder, as assessed in an initial screening interview by phone and confirmed by a structured clinical interview on the first day of the study. Exclusion Criteria for Psychiatric Subjects: 1. Subjects with a history of seizure disorder, stroke, Parkinson's disease, any form of dementia, or head injury resulting in loss of consciousness will be excluded from this study. 2. Contraindications to MRI be assessed during the screening interview and again using the NY-Presbyterian Hospital MRI Checklist prior to scanning and will also serve as exclusion criteria. They include claustrophobia; a history of metal implants (including braces, orthopedic implant, cochlear implant, implanted cardiac pacemaker, implanted cardioverter defibrillator, and ocular implant); weight over 250 pounds (owing to the size of the MR scanner bore); and women who are currently pregnant or breastfeeding. 3. Subjects who indicate that there is a chance that they may be pregnant will be asked to take a pregnancy test. They will be informed of the potential for false positive results due to diet, vitamins, and supplements, or over-the-counter medications. A positive pregnancy test will necessitate exclusion from the study, and the results will be disclosed to the participant. 4. Patients who are currently being treated with a beta blocker or daily (standing) benzodiazepines will be excluded, unless, in the judgment of the prescribing physician, the dose can be withheld on the morning of the each study session, due to the potential for these medications to mask neurobiological and cardiovascular responses to mental stress. 5. Investigators will also assess for additional psychiatric exclusion criteria during the screening interview and structured clinical interview: patients with bipolar 1 disorder who are currently manic; patients with any mood disorder currently complicated by hallucinations, delusions, or other psychotic features; patients with active suicidal ideation; and patients meeting DSM-V criteria for a co-morbid substance abuse disorder within the last 12 months will all be excluded. Other psychiatric co-morbidities will be permitted. Subjects who meet both the psychiatric and cardiac inclusion criteria will also be enrolled in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Medical College | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of mental stress induced ischemia as measured by cardiac MRI | Subjects will undergo a brief training program for low-stress version of emotion regulation task and working memory task on a laptop. Baseline (non-stress) resting cardiac MR perfusion and baseline (non-stress) brain MRI studies. In addition to a mental stress task brain fMRI and mental stress cardiac MR perfusion. We can analyze the prevalence of mental stress induced ischemia. | 2 weeks | |
Secondary | Change in cardiac stress perfusion as measured by cardiac MRI (pre and post mental stress) | We will test for within-subject changes in cardiovascular function and neural activity in stress-sensitive brain circuits, comparing pre and post-stress cardiac mRI and brain MRI studies. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05443061 -
Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children
|
N/A | |
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Recruiting |
NCT06006975 -
Early Warning of Delayed Cerebral Ischemia
|
||
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT02758847 -
Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty
|
N/A | |
Completed |
NCT02557282 -
CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol
|
||
Enrolling by invitation |
NCT02033681 -
Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution
|
N/A | |
Completed |
NCT01608035 -
Sciatic Perineural Versus Stump Catheter for Below Knee Amputation
|
Phase 0 | |
Active, not recruiting |
NCT01518842 -
Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy
|
N/A | |
Completed |
NCT01625832 -
Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)
|
N/A | |
Active, not recruiting |
NCT01281241 -
Study on Mechanical and Electrical Alternans
|
N/A | |
Completed |
NCT00778323 -
Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Terminated |
NCT00760708 -
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Completed |
NCT04879875 -
New Method for Real-time Detection of Tissue Ischemia (ISCALERT)
|
N/A | |
Completed |
NCT00526474 -
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
|
Phase 3 | |
Completed |
NCT03994822 -
pRESET for Occlusive Stroke Treatment
|
N/A | |
Completed |
NCT02910778 -
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
|
Phase 4 | |
Completed |
NCT02552498 -
Post Occlusive Reactive Hyperemia on Gingiva Assessed by Laser Speckle Contrast Imaging
|
N/A |